Tris Pharma, Inc. (Tris), a biopharmaceutical company in the commercial stage, revealed encouraging topline findings from its ALLEVIATE-1 crucial Phase 3 clinical trial assessing cebranopadol, an experimental treatment, for addressing moderate-to...
Guangzhou Fermion Technology Co., Ltd., an AI-focused biotech firm in clinical development, and Simcere Pharmaceutical Group Limited, a pharmaceutical entity, have announced a collaboration to advance a clinical-stage pain treatment asset, FZ002...
PulseSight Therapeutics SAS, a biotech firm focused on ophthalmology that creates groundbreaking non-viral vector therapies utilizing minimally-invasive delivery methods, has announced it has filed a Clinical Trial Authorization (CTA) with the...
Lyndra Therapeutics, a biopharmaceutical company in the clinical stage, has formed a strategic partnership with Thermo Fisher Scientific Inc., wherein Thermo Fisher will offer global clinical research and commercial manufacturing services to...
ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...
CAGE Bio, Inc., a biotechnology firm in clinical development focusing on novel treatments for prevalent immuno-dermatological conditions, announced the start of a phase 2b dose-ranging study for its CGB-500 product. This topical JAK inhibitor...
ModeX Therapeutics Inc, announces that the first participant has been dosed in the phase I trial (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed alongside Merck, referred to as MSD outside the U.S. and Canada...
The US Food and Drug Administration (FDA) released a draft guidance in collaboration with the Office for Human Research Protections that, once finalized, will offer suggestions for incorporating tissue biopsies into clinical trials. The draft...
Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405...